Our findings show that GLUT1 is expressed in canine OSA and confirm the need to investigate the potential of glycolytic inhibitors to increase therapeutic efficacy in both canine and human OSA. The gene discussed is SLC2A1; the disease is obstructive sleep apnea syndrome.